<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2016101130266N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-08-26</date_registration>
      <primary_sponsor>Vice Chancellor Of Research, Iran University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation the effect of pulsatile perfusion during cardiopulmonary bypass on cerebral tissue oxygenation  and arterial blood lactate  leveles  in patients  undergoing  valvular  heart  Surgery</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation the effect of pulsatile perfusion during cardiopulmonary bypass on cerebral tissue oxygenation  and arterial blood lactate  leveles  in patients  undergoing  valvular  heart  Surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2016-12-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/24109</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Other, Other design features: This study is randomized controlled clinical trial with blocked randomization.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Valvular heart disease.</hc_freetext>
      <i_freetext>Intervention 1: During open heart surgery when patient is on cardiopulmonary bypass after aortic cross clamping and cardioplegic arrest patients undergoing pulsatile perfusion.&#13;
pulsatile features on heart lung machine set as following: frequency: 70 beat per minute,  pulse width: 50%, base flow: 30%( 70%pulsatile and 30% nonpulsatile). Intervention 2: In control group during cardiopulmonary bypass after aortic cross clamping patients undergoing routine(non pulsatile) perfusion.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Samira Moosaei Far</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing &amp; Midwifery, Shahid Rashid Yasemi Street, Valiasr Street, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 919 165 0136</telephone>
        <email>samira.moosaei@gmail.commosaeifar.s@tak.iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Tahereh Najafi Ghezeljeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing &amp; Midwifery, Shahid Rashid Yasemi Street, Valiasr Street,Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip></zip>
        <telephone>+98 21 4365 1000</telephone>
        <email>najafi.t@iums.ac.ir</email>
        <affiliation>School of Nursing &amp; Midwifery of Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: patients  with valvular heart disease that needs surgical replacement or repair of heart valves, body surface area less than 2, Age 18 to 65,  Estimated cardiopulmonary bypass time greater than 60 minute, Left ventricle ejection fraction(LVEF) 40% and greater than 40%&#13;
Exclusion criteria: patients with carotid stenosis, atherosclerosis of ascending aorta and aortic arch, history of cerebrovascular accident,  diabetic patient, hepatic disorders, alcoholism,  patients needs emergency  or complicated and redo surgeries, congenital heart disease,  pregnancy, patients disagreement(without consent), preoperation  arterial lactate levels greater than 2 miliigram per deciliter, arteial blood gases not in normal rang during cardiopulmonary bypass, patients who needs intraaortic baloon pump(IABP), extracorporeal membrane oxygenation(ECMO) or patients with open sternum, cardiac arrest</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I134,I135,</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Nonrheumatic mitral valve disorders, Nonrheumatic aortic valve disorders, Nonrheumatic tricuspid valve disorders, Pulmonary valve disorders</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>During open heart surgery when patient is on cardiopulmonary bypass after aortic cross clamping and cardioplegic arrest patients undergoing pulsatile perfusion.&#13;
pulsatile features on heart lung machine set as following: frequency: 70 beat per minute,  pulse width: 50%, base flow: 30%( 70%pulsatile and 30% nonpulsatile)</i_keyword>
      <i_keyword>In control group during cardiopulmonary bypass after aortic cross clamping patients undergoing routine(non pulsatile) perfusion.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Arterial blood lactate level. Timepoint: after anasthasia and mechanical ventilation, after aortic cross clamping, after aortic cross clamp removal, termination of cardiopulmonary bypass, 2 and 4 hours post operation room. Method of measurement: arterial blood sample ( our lab reference unit is milligram per decilitre).</prim_outcome>
      <prim_outcome>Cerebral oxygenetion. Timepoint: During the whole time of surgery and cardiopulmonary bypass. Method of measurement: To evaluate cerebral oxygenetion we use INVOS cerebral /somatic oxymeter, the values are measured continuously as a percentage of oxygen saturation.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Liver enzymes(AST&amp; ALT). Timepoint: Pre &amp; Post operation. Method of measurement: blood sample(our lab reference unit is Unit per liter).</sec_outcome>
      <sec_outcome>Renal function tests( BUN &amp; Cr). Timepoint: Pre &amp; Post operation. Method of measurement: blood sample(our lab reference unit is milligram per deciliter).</sec_outcome>
      <sec_outcome>Lactate dehydrogenase(LDH). Timepoint: Pre &amp; Post operation. Method of measurement: blood sample( our lab reference unit is Unit per liter).</sec_outcome>
      <sec_outcome>Platelet count. Timepoint: Pre &amp; Post operation. Method of measurement: blood sample(our lab reference unit is platelete  count per microliters).</sec_outcome>
      <sec_outcome>Urine out put. Timepoint: Pre CPB, Pre aortic cross clamp, after removal of aortic cross clamp, termination of CPB. Method of measurement: Through direct vision urine volume(in millilite)r is measured by collecting in urine bag.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice Chancellor Of Research, Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2016-11-21</approval_date>
        <contact_name>Ethics Committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Hemmat highway, Tehran Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
